The long-term costs and effects of tubal flushing with oil-based versus water-based contrast during hysterosalpingography.


Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 05 03 2020
revised: 18 08 2020
accepted: 11 09 2020
pubmed: 21 10 2020
medline: 27 11 2021
entrez: 20 10 2020
Statut: ppublish

Résumé

What are the long-term costs and effects of oil- versus water-based contrast in infertile women undergoing hysterosalpingography (HSG)? This economic evaluation of a long-term follow-up of a multicentre randomized controlled trial involved 1119 infertile women randomized to HSG with oil- (n = 557) or water-based contrast (n = 562) in the Netherlands. In the oil-based contrast group, 39.8% of women needed no other treatment, 34.6% underwent intrauterine insemination (IUI) and 25.6% had IVF/intracytoplasmic sperm injection (ICSI) in the 5 years following HSG. In the water-based contrast group, 35.0% of women had no other treatment, 34.2% had IUI and 30.8% had IVF/ICSI in the 5 years following HSG (P = 0.113). After 5 years of follow-up, HSG using oil-based contrast resulted in equivalent costs (mean cost difference -€144; 95% confidence interval [CI] -€579 to +€290; P = 0.515) for a 5% increase in the cumulative ongoing pregnancy rate compared with HSG using water-based contrast (80% compared with 75%, Relative Risk (RR) 1.07; 95% CI 1.00-1.14). Similarly, HSG with oil-based contrast resulted in equivalent costs (mean cost difference -€50; 95% CI -€576 to +€475; P = 0.850) for a 7.5% increase in the cumulative live birth rate compared with HSG with water-based contrast (74.8% compared with 67.3%, RR 1.11; 95% CI 1.03-1.20), making it the dominant strategy. Scenario analyses suggest that the oil-based contrast medium is the dominant strategy up to a price difference of €300. Over a 5-year follow-up, HSG with an oil-based contrast was associated with a 5% increase in ongoing pregnancy rate, a 7.5% increase in live birth rate and similar costs to HSG with water-based contrast.

Identifiants

pubmed: 33077355
pii: S1472-6483(20)30520-4
doi: 10.1016/j.rbmo.2020.09.015
pii:
doi:

Substances chimiques

Contrast Media 0
Iothalamic Acid 16CHD79MIX
Ethiodized Oil 8008-53-5
ioxitalamic acid 967RDI7Z6K

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

150-157

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Nienke van Welie (N)

Department of Reproductive Medicine, Amsterdam UMC, Amsterdam Reproduction and Development Research Institute, Vrije Universiteit Amsterdam Amsterdam, the Netherlands. Electronic address: n.vanwelie@amsterdamumc.nl.

Clarabelle T Pham (CT)

Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.

Joukje van Rijswijk (J)

Department of Reproductive Medicine, Amsterdam UMC, Amsterdam Reproduction and Development Research Institute, Vrije Universiteit Amsterdam Amsterdam, the Netherlands.

Kim Dreyer (K)

Department of Reproductive Medicine, Amsterdam UMC, Amsterdam Reproduction and Development Research Institute, Vrije Universiteit Amsterdam Amsterdam, the Netherlands.

Harold R Verhoeve (HR)

Department of Obstetrics and Gynaecology, OLVG, Amsterdam, the Netherlands.

Annemieke Hoek (A)

Department of Reproductive Medicine and Gynaecology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

Jan Peter de Bruin (JP)

Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands.

Annemiek W Nap (AW)

Department of Obstetrics and Gynaecology, Rijnstate Hospital, Arnhem, the Netherlands.

Machiel H A van Hooff (MHA)

Department of Obstetrics and Gynaecology, Franciscus Hospital, Rotterdam, the Netherlands.

Mariëtte Goddijn (M)

Centre for Reproductive Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Angelo B Hooker (AB)

Department of Obstetrics and Gynaecology, Zaans Medical Centre, Zaandam, the Netherlands.

Anna P Gijsen (AP)

Department of Obstetrics and Gynaecology, Elkerliek Hospital, Helmond, the Netherlands.

Maaike A F Traas (MAF)

Department of Obstetrics and Gynaecology, Gelre Hospitals, Apeldoorn, the Netherlands.

Jesper M J Smeenk (JMJ)

Department of Obstetrics and Gynaecology, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands.

Alexander V Sluijmer (AV)

Department of Obstetrics and Gynaecology, Wilhelmina Hospital, Assen, the Netherlands.

Marieke J Lambers (MJ)

Department of Obstetrics and Gynaecology, Dijklander Hospital, Hoorn, the Netherlands.

Gijsbertus A van Unnik (GA)

Department of Obstetrics and Gynaecology, Alrijne Hospital, Leiden, the Netherlands.

Cornelia H de Koning (CH)

Department of Obstetrics and Gynaecology, Tergooi Hospital, Blaricum, the Netherlands.

Alexander Mozes (A)

Department of Obstetrics and Gynaecology, Amstelland Hospital, Amstelveen, the Netherlands.

Catharina C M Timmerman (CCM)

Department of Obstetrics and Gynaecology, Bravis Hospital, Roosendaal, the Netherlands.

Cornelis B Lambalk (CB)

Department of Reproductive Medicine, Amsterdam UMC, Amsterdam Reproduction and Development Research Institute, Vrije Universiteit Amsterdam Amsterdam, the Netherlands.

Jonathan D Karnon (JD)

Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.

Velja Mijatovic (V)

Department of Reproductive Medicine, Amsterdam UMC, Amsterdam Reproduction and Development Research Institute, Vrije Universiteit Amsterdam Amsterdam, the Netherlands.

Ben Willem J Mol (BWJ)

Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia; Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH